Matthew Baggott

@mattbagg.eurosky.social

Scientist, CEO @ Tactogen

Shouldn't last Monday's article from FDA staff have had a notice that “U.S. Government-authored contributions are in the public domain in the U.S.” rather than a copyright? It's not great when regulators speak via privately owned, paywalled channels.

Arnold et al. find that RCTs investigating neuropathic pain often contain psychiatric-related exclusion criteria, potentially reducing the generalizability to a substantial population subset that experiences comorbid psychiatric disorders #PAIN bit.ly/4coVqGs

Bild

My hypothesis is that these findings reflect more of a threshold phenomenon in which you need to get a certain number of serotonin receptors activated and beyond that there’s no additional benefit.

Bita Moghaddam@bita137.bsky.social · last mo.

Real data from real people treated with psilocybin in Oregon and Colorado hot takes: lack of a dose effect AND comparable benefits for depression and anxiety improvement in people taking SSRIs @zenbrainest.bsky.social 5HT2A occupancy matters less than context? www.medrxiv.org/content/10.6...

I wrote about the new rule proposing political oversight of every form of federal grant-making and what it means, legally, for OMB to do this. Wild it's gotten nearly 5k comments in < a week. Thanks to Carrie Wolinetz, @cdelawalla.bsky.social for their insights cen.acs.org/policy/resea...

White House move to step up political role in US research sparks alarm

An Office of Management and Budget proposal would insert political oversight into federal grant decisions, downgrade peer review, and expose all grants to termination without cause

cen.acs.org

Incredible! Scientists receive a rare standing ovation after announcing that a new treatment can double the survival time for pancreatic cancer, the deadliest cancer which was once considered “undruggable.” When we fund and support science, we can achieve anything! (Video: Dr. Wish Dhillon)